Abstract
Context.-Precision medicine is the promise of individualized therapy and management of patients based on their personal biology. There are now multiple global initiatives to perform whole-genome sequencing on millions of individuals. In the United States, an early program was the Million Veteran Program, and a more recent proposal in 2015 by the president of the United States is the Precision Medicine Initiative. To implement precision medicine in routine oncology care, genetic variants present in tumors need to be matched with effective clinical therapeutics. When we focus on the current state of precision medicine for gastrointestinal malignancies, it becomes apparent that there is a mixed history of success and failure. Objective.-To present the current state of precision medicine using gastrointestinal oncology as a model. We will present currently available targeted therapeutics, promising new findings in clinical genomic oncology, remaining quality issues in genomic testing, and emerging oncology clinical trial designs. Data Sources.-Review of the literature including clinical genomic studies on gastrointestinal malignancies, clinical oncology trials on therapeutics targeted to molecular alterations, and emerging clinical oncology study designs. Conclusions.-Translating our ability to sequence thousands of genes into meaningful improvements in patient survival will be the challenge for the next decade.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 449-460 |
| Number of pages | 12 |
| Journal | Archives of Pathology and Laboratory Medicine |
| Volume | 140 |
| Issue number | 5 |
| DOIs | |
| State | Published - May 1 2016 |
Fingerprint
ASJC Scopus subject areas
- Pathology and Forensic Medicine
- Medical Laboratory Technology
Cite this
Precision medicine in gastrointestinal pathology. / Wang, David H.; Park, Jason Y.
In: Archives of Pathology and Laboratory Medicine, Vol. 140, No. 5, 01.05.2016, p. 449-460.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Precision medicine in gastrointestinal pathology
AU - Wang, David H.
AU - Park, Jason Y.
PY - 2016/5/1
Y1 - 2016/5/1
N2 - Context.-Precision medicine is the promise of individualized therapy and management of patients based on their personal biology. There are now multiple global initiatives to perform whole-genome sequencing on millions of individuals. In the United States, an early program was the Million Veteran Program, and a more recent proposal in 2015 by the president of the United States is the Precision Medicine Initiative. To implement precision medicine in routine oncology care, genetic variants present in tumors need to be matched with effective clinical therapeutics. When we focus on the current state of precision medicine for gastrointestinal malignancies, it becomes apparent that there is a mixed history of success and failure. Objective.-To present the current state of precision medicine using gastrointestinal oncology as a model. We will present currently available targeted therapeutics, promising new findings in clinical genomic oncology, remaining quality issues in genomic testing, and emerging oncology clinical trial designs. Data Sources.-Review of the literature including clinical genomic studies on gastrointestinal malignancies, clinical oncology trials on therapeutics targeted to molecular alterations, and emerging clinical oncology study designs. Conclusions.-Translating our ability to sequence thousands of genes into meaningful improvements in patient survival will be the challenge for the next decade.
AB - Context.-Precision medicine is the promise of individualized therapy and management of patients based on their personal biology. There are now multiple global initiatives to perform whole-genome sequencing on millions of individuals. In the United States, an early program was the Million Veteran Program, and a more recent proposal in 2015 by the president of the United States is the Precision Medicine Initiative. To implement precision medicine in routine oncology care, genetic variants present in tumors need to be matched with effective clinical therapeutics. When we focus on the current state of precision medicine for gastrointestinal malignancies, it becomes apparent that there is a mixed history of success and failure. Objective.-To present the current state of precision medicine using gastrointestinal oncology as a model. We will present currently available targeted therapeutics, promising new findings in clinical genomic oncology, remaining quality issues in genomic testing, and emerging oncology clinical trial designs. Data Sources.-Review of the literature including clinical genomic studies on gastrointestinal malignancies, clinical oncology trials on therapeutics targeted to molecular alterations, and emerging clinical oncology study designs. Conclusions.-Translating our ability to sequence thousands of genes into meaningful improvements in patient survival will be the challenge for the next decade.
UR - http://www.scopus.com/inward/record.url?scp=84965056848&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84965056848&partnerID=8YFLogxK
U2 - 10.5858/arpa.2015-0317-RA
DO - 10.5858/arpa.2015-0317-RA
M3 - Article
VL - 140
SP - 449
EP - 460
JO - Archives of Pathology and Laboratory Medicine
JF - Archives of Pathology and Laboratory Medicine
SN - 0003-9985
IS - 5
ER -